Neurology

Pharmalot

ICER, the controversial cost-effectiveness watchdog, reverses course on two migraine drugs

By Ed Silverman

Pharmalot

Rising out-of-pocket costs for dementia and neuropathy drugs lower patient adherence

By Ed Silverman

First Opinion

Microglia: a new target in the brain for depression, Alzheimer’s, and more?

By Donna Jackson Nakazawa

Biotech

A venture firm warms to funding neuroscience

By Matthew Herper

Pharmalot

High cost of multiple sclerosis medicines is forcing many patients to take ‘drastic actions’

By Ed Silverman

Biotech

An uncommon form of dementia hits at a younger age. Drug makers are searching for a treatment

By Jonathan Saltzman — Boston Globe

Biotech

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

By Jonathan Saltzman — Boston Globe

Health

After Ice Bucket campaign, researchers have optimism about insights into ALS puzzle

By Felice J. Freyer — Boston Globe

In the Lab

Research using brains-in-a-dish forces a radical rethinking of Huntington’s disease

By Sharon Begley

Health

A clinical trial for Huntington’s opens the door to hope for some patients. Only so many can get in

By Andrew Joseph

In the Lab

Warning: Swimming and deep brain stimulation do not mix

By Elizabeth Cooney

Pharmalot

Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pill

By Ed Silverman

In the Lab

Long-neglected gene plays a bigger role in Alzheimer’s than suspected, study shows

By Sharon Begley

Biotech

Startup Arkuda targets rapidly advancing, rare form of dementia

By Jonathan Saltzman — Boston Globe

In the Lab

She was destined to get early Alzheimer’s, but didn’t. Did a rare mutation protect her?

By Sharon Begley

Health

Can a simple eye exam replace costly and invasive Alzheimer’s diagnostic procedures?

By Jonathan Saltzman — Boston Globe

Health

Alzheimer’s patients in Biogen trial, jolted by revival of drug, press for access once again

By Andrew Joseph

Special Report

Forecasting Alzheimer’s: With a tsunami of new diagnoses expected, experts calculate the best ways to shift the tide

By Sharon Begley

Biotech

Vertex takes on Huntington’s disease in deal with Ribometrix

By Jonathan Saltzman — Boston Globe

First Opinion

Is football bad for the brain? We know little about the long-term effects of concussions

By Munro Cullum

Health

A devastating illness rocked Uganda, then disappeared. Disabled children — and a mystery — remain

By Jacquelyn Corley

Pharmalot

Price hikes for multiple sclerosis drugs helped Medicare Part D out-of-pocket costs to skyrocket

By Ed Silverman

Health

Former NFL players with worse or more frequent concussions are more likely to show sexual dysfunction, study shows

By Lev Facher

Health Tech

With brain trauma, surgeons don’t always know if an operation will help. Could AI change that?

By Jacquelyn Corley

Politics

Alzheimer’s advocates are swarming the Iowa State Fair, pushing politicians to consider policies to fight the disease

By Nicholas Florko

Two companies bet on ‘chemogenetics’ to sidestep challenges with neurological drug development

A chronic illness conundrum: Should I tell my employer about my MS?

The U.S. needs a nationwide registry for traumatic brain injury

They have ‘Alzheimer’s brains’ but no symptoms. A new wave of drug developers wants to know why

ICER, the controversial cost-effectiveness watchdog, reverses course on two migraine drugs

Rising out-of-pocket costs for dementia and neuropathy drugs lower patient adherence

Microglia: a new target in the brain for depression, Alzheimer’s, and more?

A venture firm warms to funding neuroscience

High cost of multiple sclerosis medicines is forcing many patients to take ‘drastic actions’

An uncommon form of dementia hits at a younger age. Drug makers are searching for a treatment

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

After Ice Bucket campaign, researchers have optimism about insights into ALS puzzle

Research using brains-in-a-dish forces a radical rethinking of Huntington’s disease

A clinical trial for Huntington’s opens the door to hope for some patients. Only so many can get in

Warning: Swimming and deep brain stimulation do not mix

Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pill

Long-neglected gene plays a bigger role in Alzheimer’s than suspected, study shows

Startup Arkuda targets rapidly advancing, rare form of dementia

She was destined to get early Alzheimer’s, but didn’t. Did a rare mutation protect her?

Can a simple eye exam replace costly and invasive Alzheimer’s diagnostic procedures?

Alzheimer’s patients in Biogen trial, jolted by revival of drug, press for access once again

Forecasting Alzheimer’s: With a tsunami of new diagnoses expected, experts calculate the best ways to shift the tide

Vertex takes on Huntington’s disease in deal with Ribometrix

Is football bad for the brain? We know little about the long-term effects of concussions

A devastating illness rocked Uganda, then disappeared. Disabled children — and a mystery — remain

Price hikes for multiple sclerosis drugs helped Medicare Part D out-of-pocket costs to skyrocket

Former NFL players with worse or more frequent concussions are more likely to show sexual dysfunction, study shows

With brain trauma, surgeons don’t always know if an operation will help. Could AI change that?

Alzheimer’s advocates are swarming the Iowa State Fair, pushing politicians to consider policies to fight the disease